Clonal Sequences Recovered from Plasma from Patients with Residual HIV-1 Viremia and on Intensified Antiretroviral Therapy Are Identical to Replicating Viral RNAs Recovered from Circulating Resting CD4+ T Cells

ABSTRACT Despite successful antiretroviral therapy (ART), low-level viremia (LLV) may be intermittently detected in most HIV-infected patients. Longitudinal blood plasma and resting CD4+ T cells were obtained from two patients on suppressive ART to investigate the source of LLV. Single-genome sequencing of HIV-1 env from LLV plasma was performed, and the sequences were compared to sequences recovered from limiting-dilution outgrowth assays of resting CD4+ T cells. The circulating LLV virus clone was identical to virus recovered from outgrowth assays from pools of millions of resting CD4+ T cells. Understanding the sources of LLV requires evaluation of all possible reservoirs of persistent HIV infection.

[1]  R. Siliciano,et al.  The challenge of viral reservoirs in HIV-1 infection. , 2002, Annual review of medicine.

[2]  J. Coffin,et al.  Valproic acid without intensified antiviral therapy has limited impact on persistent HIV infection of resting CD4+ T cells , 2008, AIDS.

[3]  B. Palmer,et al.  Effects of Sustained HIV-1 Plasma Viremia on HIV-1 Gag-Specific CD4+ T Cell Maturation and Function1 , 2004, The Journal of Immunology.

[4]  James Riddell,et al.  HIV–1 Infects Multipotent Progenitor Cells Causing Cell Death and Establishing Latent Cellular Reservoirs , 2010, Nature Medicine.

[5]  S. Frost,et al.  Low‐level plasma HIVs in patients on prolonged suppressive highly active antiretroviral therapy are produced mostly by cells other than CD4 T‐cells , 2009, Journal of medical virology.

[6]  Geneviève Boucher,et al.  HIV reservoir size and persistence are driven by T cell survival and homeostatic proliferation , 2009, Nature Medicine.

[7]  M. Nei,et al.  MEGA4: Molecular Evolutionary Genetics Analysis (MEGA) software version 4.0. , 2007, Molecular biology and evolution.

[8]  L. Montaner,et al.  Advances in macrophage and dendritic cell biology in HIV‐1 infection stress key understudied areas in infection, pathogenesis, and analysis of viral reservoirs , 2006, Journal of leukocyte biology.

[9]  A. Phillips,et al.  HIV infection, antiretroviral treatment, ageing, and non-AIDS related morbidity , 2009, BMJ : British Medical Journal.

[10]  H. Chu,et al.  Quantitating the Multiplicity of Infection with Human Immunodeficiency Virus Type 1 Subtype C Reveals a Non-Poisson Distribution of Transmitted Variants , 2009, Journal of Virology.

[11]  J. Margolick,et al.  Consistent Viral Evolutionary Changes Associated with the Progression of Human Immunodeficiency Virus Type 1 Infection , 1999, Journal of Virology.

[12]  D. Hazuda,et al.  The Challenge of Finding a Cure for HIV Infection , 2009, Science.

[13]  N. Saitou,et al.  The neighbor-joining method: a new method for reconstructing phylogenetic trees. , 1987, Molecular biology and evolution.

[14]  Michael P Busch,et al.  Dynamics of HIV viremia and antibody seroconversion in plasma donors: implications for diagnosis and staging of primary HIV infection , 2003, AIDS.

[15]  A. Trkola,et al.  HIV rebounds from latently infected cells, rather than from continuing low-level replication , 2008, Proceedings of the National Academy of Sciences.

[16]  J. Mellors,et al.  Low-level viremia persists for at least 7 years in patients on suppressive antiretroviral therapy , 2008, Proceedings of the National Academy of Sciences.

[17]  John W. Mellors,et al.  Multiple, Linked Human Immunodeficiency Virus Type 1 Drug Resistance Mutations in Treatment-Experienced Patients Are Missed by Standard Genotype Analysis , 2005, Journal of Clinical Microbiology.

[18]  M. Nei,et al.  Prospects for inferring very large phylogenies by using the neighbor-joining method. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[19]  Anthony S. Fauci,et al.  Relationship between pre-existing viral reservoirs and the re-emergence of plasma viremia after discontinuation of highly active anti-retroviral therapy , 2000, Nature Medicine.

[20]  Hui Li,et al.  Identification and characterization of transmitted and early founder virus envelopes in primary HIV-1 infection , 2008, Proceedings of the National Academy of Sciences.

[21]  M. Kimura.  A simple method for estimating evolutionary rates of base substitutions through comparative studies of nucleotide sequences , 1980, Journal of Molecular Evolution.

[22]  J Witek,et al.  Residual HIV-1 RNA in blood plasma of patients taking suppressive highly active antiretroviral therapy. , 1999, JAMA.

[23]  Joseph A Kovacs,et al.  ART Suppresses Plasma HIV-1 RNA to a Stable Set Point Predicted by Pretherapy Viremia , 2007, PLoS pathogens.

[24]  J. Alcamí,et al.  Understanding HIV-1 latency provides clues for the eradication of long-term reservoirs , 2009, Nature Reviews Microbiology.

[25]  Claus O. Wilke,et al.  Residual Human Immunodeficiency Virus Type 1 Viremia in Some Patients on Antiretroviral Therapy Is Dominated by a Small Number of Invariant Clones Rarely Found in Circulating CD4+ T Cells , 2006, Journal of Virology.

[26]  M. Lederman,et al.  The Effect of Raltegravir Intensification on Low-level Residual Viremia in HIV-Infected Patients on Antiretroviral Therapy: A Randomized Controlled Trial , 2010, PLoS medicine.

[27]  C. Crumpacker,et al.  Hematopoietic stem and progenitor cells in HIV/AIDS and immune reconstitution , 2010, Cell Research.

[28]  John M. Coffin,et al.  Antiretroviral Intensification and Valproic Acid Lack Sustained Effect on Residual HIV-1 Viremia or Resting CD4+ Cell Infection , 2010, PloS one.

[29]  D. Margolis,et al.  Attacking HIV provirus: therapeutic strategies to disrupt persistent infection. , 2006, Infectious disorders drug targets.

[30]  J. Thompson,et al.  CLUSTAL W: improving the sensitivity of progressive multiple sequence alignment through sequence weighting, position-specific gap penalties and weight matrix choice. , 1994, Nucleic acids research.

[31]  John W. Mellors,et al.  New Real-Time Reverse Transcriptase-Initiated PCR Assay with Single-Copy Sensitivity for Human Immunodeficiency Virus Type 1 RNA in Plasma , 2003, Journal of Clinical Microbiology.

[32]  John O. Woods,et al.  Analysis of Human Immunodeficiency Virus Type 1 Viremia and Provirus in Resting CD4+ T Cells Reveals a Novel Source of Residual Viremia in Patients on Antiretroviral Therapy , 2009, Journal of Virology.

[33]  B. Korber,et al.  Deciphering Human Immunodeficiency Virus Type 1 Transmission and Early Envelope Diversification by Single-Genome Amplification and Sequencing , 2008, Journal of Virology.